Background \& Rationale: Treatment options for Parkinson's Disease (PD) often face challenges due to the variety of clinical subtypes, differing individual responses, and disease progression. Given its portability, affordability, safety, and ease of use, cerebellar transcranial direct current stimulation (ctDCS) presents as a promising option for home-based treatment with medical telemonitoring in the near future. Study Procedures: Participants are invited to complete questionnaires regarding quality of life, anxiety and depression, and symptoms related to their PD. On the first day, they will be assessed using the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III for motor impairment and the Cerebellar Cognitive Affective Syndrome scale (CCAS) for cognitive impairment. Participants will then undergo an additional 8 days of at-home cTDCS stimulation. On the 10th day, they will be reassessed using the MDS-UPDRS III and CCAS. One month later, they will complete again the questionnaires regarding quality of life, anxiety, depression, and symptoms related to their PD. Objective: Consequently, the primary goal is to investigate the effectiveness of ctDCS in addressing both motor and non-motor symptoms of PD
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
25
Hopital Erasme
Brussels, Belgium
MDS-UPDRS (Unit on a scale)
MDS-UPDRS Part III MDS-UPDRS Part I, II and IV
Time frame: day 1 to day 10 (MDS-UPDRS III) day 1 to day 40 (MDS-UPDRS Part I, II and IV)
CCAS (Unit on a scale)
CCAS scale
Time frame: day 1 and day 10
Feasibility and tolerability of ctDCS (Unit on a scale)
participant-reported outcomes regarding the ease of self-administration and the presence of side effects are collected through a dedicated questionnaire.
Time frame: from day 1 to day 10
Scale evaluation anxiety (Unit on a scale)
anxiety as evaluated by Generalized Anxiety Disorder-7 (GAD-7)
Time frame: day 1 and day 40
Scale evaluating depression (Unit on a scale)
depression as evaluated by Patient Health Questionnaire-9 (PHQ-9 )
Time frame: day 1 and day 40
Quality of life (Unit on a scale)
quality of life as evaluated by Parkinson's Disease Questionnaire-39 (PDQ-39)
Time frame: day 1 and day 40
Scale evaluation anxiety (Unit on a scale)
anxiety as evaluated by Beck Anxiety Inventory (BAI)
Time frame: day 1 and day 40
Scale evaluating depression (Unit on a scale)
depression as evaluated by Beck Depression Inventory (BDI)
Time frame: day 1 and day 40
Quality of life (Unit on a scale)
quality of life as evaluated by European Quality of Life 5 Dimensions (EQ-5D)
Time frame: day 1 and day 40
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.